智通财经APP讯，科伦博泰生物(06990)发布公告，本公司已收到国家药品监督管理局(NMPA)药品审评中心(CDE)同意新型双载荷ADC药物SKB565新药临床试验(IND)申请的临床试验通知书，用于治疗晚期实体瘤。这是本公司首个进入临床阶段的双载荷抗体偶联药物(ADC)。
凭藉在ADC领域的技术沉淀与平台优势，本公司已布局一系列结合高价值靶点、差异化设计并具备全球潜力的创新分子。在此基础上，本公司进一步拓展“ADC+肿瘤免疫学(IO)”策略-一方面聚焦优质联用疗法的探索，包括正在临床进行中的多种ADC与程序性细胞死亡蛋白(配体)1 (PD-(L)1) 单克隆抗体联合方案，以及PD-1╱血管内皮生长因子(VEGF)双特异性抗体SKB118与本公司众多专有ADC系列资产的联用;另一方面推进一体化策略研发，在单一ADC分子中整合具有协同作用机制的功能元件。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.